Similarly acting agents from Merck & Co and Altimmune aim to improve NAFLD, with mixed results.
Vivace Therapeutics clinically validates a new mechanism, though its rival Ikena reckons more specificity is needed to avoid toxicity.
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
A Her2-positive cancer is the setting for a Keytruda triplet that could influence the trial design of some immune-stimulating agents.
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.